Spruce Biosciences Inc (SPRB)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$45.15-1.85%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Spruce Biosciences Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

0.90 → 0.90 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	3.77M
EPS	—	-5.337
Annual ending 2026-12-31
Revenue	—	53.75M
EPS	—	-25.744
Annual ending 2027-12-31
Revenue	—	78.7M
EPS	—	0.897

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash runway into early 2027	The company has $107.3 million cash to fund operations into early 2027.	Under Pressure	Cash falls below $100M before early 2027	Cash and cash equivalents: $96.295M FY2026-Q2; GAAP. Published target: Cash and equivalents >= $100M into early 2027. The stored target says 2027-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source date unavailable96,295,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents rose from $54.1M in 2026-Q1 to $96.3M in 2026-Q2, supported by a $69M public offering and a $50M term loan. Management expects this to fund operations into early 2027, beyond the BLA submission. The trajectory shows delivering on maintaining runway. Delivery assessment Oct 24, 2026
EPS turns positive in 2027	Analysts expect a positive EPS of $4.95 in 2027, up from losses in 2026.	Under Pressure	EPS remains negative or below $0 in 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance TA-ERT biologics license application submission	Spruce Biosciences aims to advance its TA-ERT drug approval by Q4 2026.	Intact	BLA submission delayed beyond Q4 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management consistently anticipates the BLA submission for TA-ERT in Q4 2026. Financials show ongoing investment in R&D with expenses of $12.2M in 2026-Q2 and $7.6M in 2026-Q1 supporting this. The trajectory is delivering as planned toward this regulatory milestone. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.90

$3.10 → $0.90 · observed estimates

FY2027 revenue$0.08B

$0.09B → $0.08B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.10	$86,766,625	5 / 6
2026-07-25	$3.10	$86,766,625	5 / 6
2026-07-26	$3.10	$86,766,625	5 / 6
2026-07-27	$3.10	$86,766,625	5 / 6
2026-07-28	$3.10	$86,766,625	5 / 6
2026-07-29	$3.10	$86,766,625	5 / 6
2026-07-30	$3.10	$86,766,625	6 / 6
2026-07-31	$7.38	$86,413,250	7 / 8
2026-08-01	$3.10	$86,766,625	6 / 6
2026-08-02	$7.38	$86,413,250	7 / 8
2026-08-03	$3.10	$86,766,625	6 / 6
2026-08-04	$3.10	$86,766,625	6 / 6
2026-08-05	$7.38	$86,413,250	7 / 8
2026-08-06	$7.38	$86,413,250	7 / 8
2026-08-08	$7.38	$86,413,250	7 / 8
2026-08-09	$7.38	$86,413,250	7 / 8
2026-08-10	$7.38	$86,413,250	7 / 8
2026-08-12	$3.10	$86,766,625	6 / 6
2026-08-13	$7.38	$86,413,250	7 / 8
2026-08-14	$3.10	$86,766,625	6 / 6
2026-08-15	$3.10	$86,766,625	6 / 6
2026-08-16	$3.10	$86,766,625	6 / 6
2026-08-17	$3.10	$86,766,625	6 / 6
2026-08-18	$3.10	$86,766,625	5 / 6
2026-08-19	$3.10	$86,766,625	5 / 6
2026-08-20	$3.12	$88,563,250	5 / 6
2026-08-21	$3.12	$88,563,250	6 / 6
2026-08-22	$3.12	$88,563,250	6 / 6
2026-08-23	$3.12	$88,563,250	6 / 6
2026-08-24	$3.12	$88,563,250	6 / 6
2026-08-25	$3.12	$88,563,250	6 / 6
2026-08-26	$3.12	$88,563,250	6 / 6
2026-08-27	$3.12	$88,563,250	6 / 6
2026-08-28	$3.12	$88,563,250	6 / 6
2026-08-29	$3.19	$88,559,125	6 / 6
2026-08-30	$3.19	$88,559,125	6 / 6
2026-08-31	$3.19	$88,559,125	6 / 6
2026-09-01	$3.19	$88,559,125	6 / 6
2026-09-02	$3.19	$88,559,125	6 / 6
2026-09-03	$3.19	$88,559,125	6 / 6
2026-09-04	$3.19	$88,559,125	6 / 6
2026-09-05	$3.19	$88,559,125	6 / 6
2026-09-06	$3.19	$88,559,125	6 / 6
2026-09-07	$3.19	$88,559,125	6 / 6
2026-09-08	$3.19	$88,559,125	6 / 6
2026-09-09	$3.19	$88,559,125	6 / 6
2026-09-10	$3.19	$88,559,125	6 / 6
2026-09-11	$3.19	$88,559,125	6 / 6
2026-09-12	$3.19	$88,559,125	6 / 6
2026-09-13	$3.19	$88,559,125	6 / 6
2026-09-14	$3.19	$88,559,125	6 / 6
2026-09-15	$3.19	$88,559,125	6 / 6
2026-09-16	$3.19	$88,559,125	6 / 6
2026-09-17	$3.19	$88,559,125	6 / 6
2026-09-18	$3.19	$88,559,125	6 / 6
2026-09-19	$3.19	$88,559,125	6 / 6
2026-09-20	$0.90	$78,719,222	6 / 7
2026-09-21	$0.90	$78,719,222	6 / 7
2026-09-22	$0.90	$78,719,222	6 / 7
2026-09-23	$0.90	$78,719,222	6 / 7
2026-09-24	$0.90	$78,719,222	6 / 7
2026-09-25	$0.90	$78,719,222	6 / 7
2026-09-26	$0.90	$78,697,000	6 / 7
2026-09-27	$0.90	$78,697,000	6 / 7
2026-09-28	$0.90	$78,697,000	6 / 7
2026-09-29	$0.90	$78,697,000	6 / 7
2026-09-30	$0.90	$78,697,000	6 / 7
2026-10-01	$0.90	$78,697,000	6 / 7
2026-10-02	$0.90	$78,697,000	6 / 7
2026-10-03	$0.90	$78,697,000	6 / 7
2026-10-04	$0.90	$78,697,000	6 / 7
2026-10-05	$0.90	$78,697,000	6 / 7
2026-10-06	$0.90	$78,697,000	6 / 7
2026-10-07	$0.90	$78,697,000	6 / 7
2026-10-08	$0.90	$78,697,000	6 / 7
2026-10-09	$0.90	$78,697,000	6 / 7
2026-10-10	$0.90	$78,697,000	6 / 7
2026-10-11	$0.90	$78,697,000	6 / 7
2026-10-12	$0.90	$78,697,000	6 / 7
2026-10-13	$0.90	$78,697,000	6 / 7
2026-10-14	$0.90	$78,697,000	6 / 7
2026-10-15	$0.90	$78,697,000	6 / 7
2026-10-16	$0.90	$78,697,000	6 / 7
2026-10-17	$0.90	$78,697,000	6 / 7
2026-10-18	$0.90	$78,697,000	6 / 7
2026-10-19	$0.90	$78,697,000	6 / 7
2026-10-20	$0.90	$78,697,000	6 / 7
2026-10-21	$0.90	$78,697,000	6 / 7
2026-10-22	$0.90	$78,697,000	6 / 7
2026-10-23	$0.90	$78,697,000	6 / 7
2026-10-24	$0.90	$78,697,000	6 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	7	0	0
2026-07-01	8	0	0
2026-08-01	8	0	0
2026-09-01	9	0	0
2026-10-01	9	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

B.Riley FinancialOct 5

$160.00New observation · no comparable prior

$0$88.00$176.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash runway into early 2027Published status: Under Pressure
EPS turns positive in 2027Published status: Under Pressure
Advance TA-ERT biologics license application submissionDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-70.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Spruce Biosciences Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making development-stage business with a speculative growth profile, not a durable compounder today. Its long-term thesis is in the watch state: management is progressing toward a TA-ERT filing, but recent results are weak and the overall signal has turned cautious.

What's priced into Spruce Biosciences Inc

The valuation model indicates SPRB trades at a 70.15% premium to peers, with optionality, or the possibility of future product value, driving the gap. Model confidence is low, and the evidence does not spell out specific market expectations, so the premium is difficult to assess against the business’s current losses and execution risks.

What the fundamentals likely do

Near term, consecutive earnings misses and an elevated risk of another miss leave results vulnerable; the latest reported miss was in August 2026. Over the multi-year view, management is targeting a TA-ERT regulatory submission by Q4 2026 and has added commercial and clinical leaders, while cash is expected to fund operations into early 2027; these plans are progress markers, not proof of eventual commercial success.

What Spruce Biosciences Inc hinges on

The thesis hinges on reaching the planned TA-ERT filing and maintaining enough cash to support the program beyond that milestone. A guidance cut or further weakening in jobs data would add pressure, while continued strength among healthcare bellwethers could support the sector backdrop.